[ad_1]
PHOTOModerna announced in a statement that its Covid vaccine is 94.5% effective. After that of AstraZeneca and the University of Oxford, the EMA (European Medicines Agency) has begun to analyze the data of the anti-Covid mRna-1273 vaccine developed by Moderna Biotech Spain, a company controlled by the American company Moderna. As the EMA points out on its website, it was decided to start with the continuous review procedure, the first step of the approval process, based on the preliminary results of non-clinical studies and the first clinical studies carried out in adults, which seem to indicate that the vaccine stimulates the production of antibodies and immune T cells against the SarsCov2 virus.
The Moderna company has announced a longer shelf life for its mRNA-1273, a COVID-19 vaccine candidate, at “refrigeration temperatures.” The candidate vaccine is expected to remain stable at standard refrigeration temperatures between 2 ° and 8 ° C for 30 days, compared to the previous estimate of 7 days. Furthermore, long-term storage and transport conditions are expected at standard freezing temperatures of -20 ° C for 6 months. The company announced it.
Phase 3 trial begins for another coronavirus vaccine candidate. It belongs to Janssen, a pharmaceutical company run by the multinational chemical company Johnson & Johnson. It is the third to reach this passage among those developed in Great Britain, after the prototype developed by the University of Oxford together with AstraZeneca with the collaboration of the Italian Irbm of Pomezia (first in the West to enter phase 3) and that of Novavax . Phase 3 of the Janssen vaccine, UK Health Minister Matt Hancock confirms, begins today and will involve 7,000 volunteers in the UK and 23,000 in other countries. It’s a vaccine model “very similar to the Oxford / AstraZeneca one,” Saul Faust, director of the Southampton laboratory coordinating the research project, told SkyNews.
REPRODUCTION RESERVED © Copyright ANSA
